CANCER Cancer
$0.00006911
$0.061676
(0.21%)
Mkt Cap$67,147.00
Vol187.84
About Cancer
Astrofolio taps into current cultural trends by referencing memes and popular narratives within the crypto space. It allows users to speculate on or invest in cryptocurrencies based on astrological signs, which is a novel approach in the crypto space. This fusion of ancient wisdom with modern financial technology creates a unique niche for enthusiasts of both fields. Cancer, the Crab , captures the nurturing and protective energy of early summer, from mid-June to mid-July. Known for its emotional depth and loyalty, Cancer season is a time to focus on home and family. Connect with the intuitive and compassionate spirit of Cancer!
ImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment
TLDR ImmunityBio stock tumbles 7.25% to $9.27 despite promising ANKTIVA trial data. ANKTIVA delivers a 71% complete response rate in a 100-patient bladder cancer trial. Bladder cancer responses last a median 26.6 months, with some beyond 53 months. Three-year data show 84% cystec...
Blockonomi
ImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment
TLDR ImmunityBio stock tumbles 7.25% to $9.27 despite promising ANKTIVA trial data. ANKTIVA delivers a 71% complete response rate in a 100-patient bladder cancer trial. Bladder cancer responses last a median 26.6 months, with some beyond 53 months. Three-year data show 84% cystec...
Blockonomi
ImmunityBio (IBRX) Stock: Climbs as FDA Expands ANKTIVA Approval for Bladder Cancer
TLDR IBRX climbs 1.12% to $9.91 as FDA expands ANKTIVA’s bladder cancer approval. FDA clears ANKTIVA plus BCG for papillary-only bladder cancer patients in the U.S. ANKTIVA’s wider label opens treatment to more patients with BCG-resistant tumors. Clinical trial finds 62% complete...
Blockonomi
Foghorn Therapeutics (FHTX) Plummets 49% as Eli Lilly Terminates Cancer Partnership
Foghorn Therapeutics (FHTX) plunged 49% after Eli Lilly terminated their cancer drug partnership following poor Phase 1 results. Company cuts 40% of staff. The post Foghorn Therapeutics (FHTX) Plummets 49% as Eli Lilly Terminates Cancer Partnership appeared first on Blockonomi.
Blockonomi
DataMEDS AI (MEDS) Stock Soars 87% Following Helomics Cancer Lab Acquisition
DataMEDS AI (MEDS) stock soared 87% after finalizing its $1.5M Helomics acquisition, gaining access to the $40B U.S. cancer diagnostics market. The post DataMEDS AI (MEDS) Stock Soars 87% Following Helomics Cancer Lab Acquisition appeared first on Blockonomi.
Blockonomi
DoubleDown Interactive (DDI) Stock: Casino Giveaway Supports Animal Welfare
TLDR DDI stock trades at $12.74 as DoubleDown unveils its $10,000 ASPCA donation. Huggable Hounds giveaway launches September 13 inside the DoubleDown Casino app. DoubleDown links its charity push with Hug Your Hound Day player engagement. The ASPCA donation follows recent suppor...
Blockonomi
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short
Tyra Biosciences (TYRA) stock plunged 22% after its bladder cancer drug dabogratinib achieved a 64% response rate, missing the 70% analyst benchmark. The post Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short appeared first on Blockonomi.
Blockonomi
Pfizer (PFE) Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
Pfizer (PFE) stock touched a 52-week high of $29.09 after Q2 earnings exceeded forecasts and the company settled over 6,000 Depo-Provera lawsuits. The post Pfizer (PFE) Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement appeared first on Blockonom...
Blockonomi
BioAffinity Technologies (BIAF) Stock Jumps 55% on CyPath Lung Cancer Survivor Monitoring News
BioAffinity Technologies (BIAF) stock rallied 55% after revealing CyPath Lung's potential to monitor lung cancer survivors for recurrence. Volume hit 17M shares. The post BioAffinity Technologies (BIAF) Stock Jumps 55% on CyPath Lung Cancer Survivor Monitoring News appeared first...
Blockonomi
Agenus Inc. (AGEN) Stock: BOT+BAL Delivers 21.2-Month Survival in Colorectal Cancer Trial
TLDR BOT+BAL delivers 21.2-month median survival in refractory MSS colorectal cancer. Three-year overall survival reaches 33% in Agenus’ fully enrolled Phase 1b cohort. Confirmed response rate hits 21%, including three complete and 23 partial responses. BOT+BAL responses appear e...
Blockonomi
BioNTech (BNTX) Shares Plunge 8% Following Colorectal Cancer Vaccine Trial Discontinuation
BioNTech (BNTX) shares dropped 8% after discontinuing its Phase 2 mRNA colorectal cancer vaccine trial due to futility and survival imbalances. The post BioNTech (BNTX) Shares Plunge 8% Following Colorectal Cancer Vaccine Trial Discontinuation appeared first on Blockonomi.
Blockonomi
Bullish/Bearish Forum Sentiment
Indicates whether most users posting on a crypto’s stream over the last 24 hours are bearish or bullish.
0
25
50
75
100
Extremely
Bearish
Neutral
Bullish
Extremely
Bearish
Bullish
N/A
Last score
N/A
1 day ago
Sign Up / Log In
1 week ago
Sign Up / Log In
1 month ago
Sign Up / Log In
3 months ago
Sign Up / Log In
6 months ago
Sign Up / Log In
1 year ago
Sign Up / Log In
Message Board Activity
Measures the total amount of chatter on a stream over the last 24 hours.
0
25
50
75
100
Extremely
Low
Normal
High
Extremely
Low
High
N/A
Last score
N/A
1 day ago
Sign Up / Log In
1 week ago
Sign Up / Log In
1 month ago
Sign Up / Log In
3 months ago
Sign Up / Log In
6 months ago
Sign Up / Log In
1 year ago
Sign Up / Log In
Discussion Diversity
Measures the number of unique accounts posting on a stream relative to the number of total messages on that stream.
0
25
50
75
100
Extremely
Low
Normal
High
Extremely
Low
High
N/A
Last score
N/A
1 day ago
Sign Up / Log In
1 week ago
Sign Up / Log In
1 month ago
Sign Up / Log In
3 months ago
Sign Up / Log In
6 months ago
Sign Up / Log In
1 year ago
Sign Up / Log In
Date
Market Cap
Volume
Close
October 18, 2026
$67,147.23
$187.84
$0.0000671514
October 18, 2026
$68,757.23
$452.31
$0.0000687615
October 17, 2026
$64,842.28
$746.25
$0.0000648463
October 16, 2026
$62,587.98
$25.22
$0.0000625919
October 15, 2026
$61,376.71
$6.85
$0.0000613806
October 14, 2026
$63,258.04
$4.83
$0.000063262
October 13, 2026
$61,920.79
$29.25
$0.0000619247
October 12, 2026
$65,382.06
$99.98
$0.0000653862
October 11, 2026
$63,233.00
$5.71
$0.000063237
October 10, 2026
$63,053.33
$17.25
$0.0000630573
Fundamentals
50
Neutral Sentiment
How do you feel about CANCER?
Advertisement|Remove ads.
Latest CANCER News
ViewImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment
Blockonomi
ImmunityBio (IBRX) Stock: Climbs as FDA Expands ANKTIVA Approval for Bladder Cancer
Blockonomi
Foghorn Therapeutics (FHTX) Plummets 49% as Eli Lilly Terminates Cancer Partnership
Blockonomi
StocktwitsPolls25
82
SLS11
13StocktwitsPolls62
106